Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: Last week […]
December 11 Biotech Update
As I noted yesterday, the market seems to have no memory day to day and despite a bad open and close, the market is higher today as if nothing happened. That is fine as it is also taking the biotech sector higher and there may be some slight outperformance with the SMID names but it […]
December 10 Biotech Update
It was a slightly negative open to the market but certainly more benign than yesterday where the market was able to come back. It may be the case that we are in a Europe driven pattern where there is selling pressure when the European markets are open but that drag is lifted once they close […]
CBSTZ: a low probability, high impact special situation
This week started with a merger Monday. Cubist Pharmaceuticals agreed to be acquired by Merck & Company for $9.5B including assumption of debt. CBST traded like one would expect on Monday, just below the offer price. However, a Contingent Value Right (CVR) with the ticker CBSTZ traded up to $0.081 on Monday, which represents a […]
December 9 Biotech Update
The market is pretty crappy to start this morning but let us see if the trend reverses. We have had a lot gap higher opens and then weakness the rest of the day, so perhaps this is a gap down and then strengthen sort of day. I do not think that is going to be […]
December 8 Biotech Update
It has been a busy couple of days as expected and more news than can be adequately covered in one day, so today I will touch on what seems most interesting and/or near term actionable. Even then I will necessarily be leaving some important topics for later in the week so feel free to contact […]
BMY – A Bull Flag Breakout or A Head Fake
Bristol-Myers Squibb Company (BMY) -NYSE Interesting price action since October 15th, after touching the support line $47.52 and bouncing back to start a new uptrend, we were looking to reach at least the last 52-weeks high at $57.49 . But BMY’s price spike even higher reaching new 52-weeks high $59.03 on October 30th after reporting […]
December 5 Biotech Update
Another day and another morning with an opening spike in large cap biotechs that was immediately sold. This is a disturbing pattern and one that needs to break if the sector is going to continue to move higher. Until we can get follow through on these opening moves, we are going to at best treat […]
Catalyst Watch – Vol. 2, Edition 34 (12/5/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: The company […]
December 4 Biotech Update
A blah start to the trading day. There are not a particularly large numbers of movers and the market seems for the most part to be drifting. As such, it is difficult to discern any real trend outside of chop. So it seems like the market and sector are searching for a direction. I would […]
December 3 Biotech Update
It is a basically neutral day in the market but the sector seems a little weak but this is off of a good day yesterday. One problem to keep an eye on is that many of the stocks I follow start very strong but weaken throughout the day. I would certainly prefer to stop seeing […]
Quick Note on GWPH
GWPH has been on one huge rollercoaster. After climbing back from $61 in mid-October to $80 in late November, it has given up 15% in just the last 3 trading days, falling back to $68 as the rest of biotech surges following their morning Q3 conference call. Perhaps investors had been expecting more detailed data […]
December 1 Bitoech Update
Markets are weak and the biotech sector is moving with it and it appears that small cap and momentum plays are being most affected (large caps seem to be holding up fairly well). The market probably needs to consolidate its recent move as do a lot of biotechs but the wild cards this month are […]
November 26 Biotech Update
The trading is winding down as we approach Thanksgiving and I suspect today is going to be slow and get slower. The market will be open again on Friday but will likely be even slower as many will likely take the half trading day off. I suspect this also means that news flow will also […]
Quick Survery
We are constantly looking for was to improve Chimera and ensure that everyone is getting value for their money. As part of this process, we are looking for feedback from you all. Please take the time to fill out this quick survey, so we can learn where we need to improve and what you find […]
November 24 Biotech Update
A decent start to the week but volume is going to be low all week and I suspect that will increase the chop. So I would not read anything into the broader sector outside of this week having a slight positive bias. That being said, we do have to respect any move that is done […]
What to Look For at ASH 2014
The year is nearly over, though it feels like scientific conferences never end. December 6th marks the last big Cancer meeting of the year- then we turn the page to 2015. We’ve put together a list of over a dozen companies presenting at ASH, along with data we believe investors will be looking for: AGIO […]
November 21 Biotech Update
A great open for the market but then it immediately proceeded to lay an egg. It is still early and the key is going to be how it responds to the selling. The only worrying sign is that the downdraft really seemed to hit biotechs and these have been a leading indicator of larger market […]
Catalyst Watch – Vol. 2, Edition 33 (11/20/14)
Below are current tactical and strategic thoughts on approaching FDA and clinical trial catalysts for select names. Estimates, values and views are as of the date published (or are noted), are subject to potential future, pre-catalyst revision and are not intended as investment recommendations. Please read our Disclaimer: (1) Catalyst Watch List: RMTI: The company […]
November 20 Biotech Update
Market starts a little weak this morning and generally is taking the sector with it. That being said it is not a rout by any means, so it seems like there sector is looking to find its footing before the next move. Luckily we have some news to talk about. 1. EPZM reported very positive […]
